WebIpsat Therapies Ltd. Ipsat Therapies Ltd. United States C Corporation No tags have been applied so far. Sign in to add some. Profile People (0) Documents (0) Dockets (0) Attorneys (0) Markets (0) Patents (1) Trademarks (0) Payments (0) Related (0) WebIPSAT THERAPIES OY has a total of 39 patent applications. Its first patent ever was published in 2000. It filed its patents most often in Australia, Canada and Finland. Its main …
The Pew Charitable Trusts The Pew Charitable Trusts
WebBiotie Therapies Finland Listed Biotie (Turku, Finland) is a specialized drug development company focused on the development of drugs for neurodegenerative and psychiatric … WebMar 23, 2009 · The active ingredient of Ipsat P1A capsule is P1A protein. P1A protein is a recombinant class A β-lactamase with a molecular mass of 29 kDa which is capable of hydrolyzing penicillin, aminopenicillins (e.g., ampicillin), and … trenazer tacx
Ipsat Therapies Ltd - Suomen Bioteollisuus
WebJun 19, 2007 · IPSAT THERAPIES OY Patent: Patent - Canada Application: CA20072659691 on 19 Jun 2007 Publication: 19 Jun 2007 PAT: CA2659691 . Patent. Share this article Share with email Share with twitter Share with linkedin Share with facebook. Abstract . The invention relates to targeted post translational modification of meta llo-beta-lactamase by ... WebDec 26, 2014 · Helsinki, Finland(24 th January 2006) -- IpsatTherapies, a Finnish biopharmaceutical company with a novel approach tofighting hospital acquired infections … Weband IPSAT Therapies, Espoo, Finland We hypothesized that orally administered, recombinant class A ^-lactamase would inactivate the portion of parenteral pi-peracillin excreted into the intestinal tract, preserving colo-nization resistance of mice against nosocomial pathogens. Sub-cutaneous piperacillin or piperacillin plus oral ^-lactamase trena proa